Literature DB >> 34112163

Echinacoside exerts anti-tumor activity via the miR-503-3p/TGF-β1/Smad aixs in liver cancer.

Wen Li1, Jing Zhou2, Yajie Zhang2, Jing Zhang2, Xue Li2, Qiao Yan2, Jiabing Han2, Fangdi Hu3.   

Abstract

BACKGROUND: Echinacoside (ECH) is the main active ingredient of Cistanches Herba, which is known to have therapeutic effects on metastatic tumors. However, the effects of ECH on liver cancer are still unclear. This study was to investigate the effects of ECH on the aggression of liver cancer cells.
METHODS: Two types of liver cancer cells Huh7 and HepG2 were treated with different doses of ECH at different times and gradients. MTT and colony formation assays were used to determine the effects of ECH on the viability of Huh7 and HepG2 cells. Transwell assays and flow cytometry assays were used to detect the effects of ECH treatment on the invasion, migration, apoptosis and cell cycle of Huh7 and HepG2 cells. Western blot analysis was used to detect the effects of ECH on the expression levels of TGF-β1, smad3, smad7, apoptosis-related proteins (Caspase-3, Caspase-8), and Cyto C in liver cancer cells. The relationship between miR-503-3p and TGF-β1 was detected using bioinformatics analysis and Luciferase reporter assay.
RESULTS: The results showed that ECH inhibited the proliferation, invasion and migration of Huh7 and HepG2 cells in a dose- and time-dependent manner. Moreover, we found that ECH caused Huh7 and HepG2 cell apoptosis by blocking cells in S phase. Furthermore, the expression of miR-503-3p was found to be reduced in liver tumor tissues, but ECH treatment increased the expression of miR-503-3p in Huh7 and HepG2 cells. In addition, we found that TGF-β1 was identified as a potential target of miR-503-3p. ECH promoted the activation of the TGF-β1/Smad signaling pathway and increased the expression levels of Bax/Bcl-2. Moreover, ECH could trigger the release of mitochondrial Cyto C, and cause the reaction Caspases grade.
CONCLUSIONS: This study demonstrates that ECH exerts anti-tumor activity via the miR-503-3p/TGF-β1/Smad aixs in liver cancer, and provides a safe and effective anti-tumor agent for liver cancer.

Entities:  

Keywords:  Apoptosis; Echinacoside; Liver cancer; MiR-503-3p; TGF-β1/smad

Year:  2021        PMID: 34112163     DOI: 10.1186/s12935-021-01890-3

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  1 in total

1.  Reduced N-acetylglucosaminyltransferase III expression via Smad3 and Erk signaling in TGF-β1-induced HCC EMT model.

Authors:  Cuiju Mo; Tianhua Liu; Shu Zhang; Kun Guo; Meng Li; Xue Qin; Yinkun Liu
Journal:  Discov Med       Date:  2017-01       Impact factor: 2.970

  1 in total
  4 in total

1.  Exploration of the Effect and Potential Mechanism of Echinacoside Against Endometrial Cancer Based on Network Pharmacology and in vitro Experimental Verification.

Authors:  Wan Shu; Ziwei Wang; Rong Zhao; Rui Shi; Jun Zhang; Wei Zhang; Hongbo Wang
Journal:  Drug Des Devel Ther       Date:  2022-06-16       Impact factor: 4.319

2.  RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma.

Authors:  Shijie Chen; Jin Zeng; Liping Huang; Yi Peng; Zuyun Yan; Aiqian Zhang; Xingping Zhao; Jun Li; Ziting Zhou; Sidan Wang; Shengyu Jing; Minghua Hu; Yuezhan Li; Dong Wang; Weiguo Wang; Haiyang Yu; Jinglei Miao; Jinsong Li; Youwen Deng; Yusheng Li; Tang Liu; Dabao Xu
Journal:  J Transl Med       Date:  2022-05-14       Impact factor: 8.440

3.  Exploring the Molecular Mechanism of lncRNA-miRNA-mRNA Networks in Non-Syndromic Cleft Lip with or without Cleft Palate.

Authors:  Xiangpu Wang; Siyuan Guo; Xinli Zhou; Yupei Wang; Ting Zhang; Renji Chen
Journal:  Int J Gen Med       Date:  2021-12-16

4.  MicroRNA-200b-3p restrains gastric cancer cell proliferation, migration, and invasion via C-X-C motif chemokine ligand 12/CXC chemokine receptor 7 axis.

Authors:  Dinuo Li; Qiang Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.